Glioblastoma (GB), a grade IV glioma, with high heterogeneity and chemoresistance, obligates a multidimensional antagonist to debilitate its competence. Considering the previous reports on thioesters as antitumor compounds, this paper investigates on use of this densely functionalized sulphur rich molecule as a potent anti-GB agent. Bio-evaluation of 12 novel compounds, containing α-thioether ketone and orthothioester functionalities, identified that five analogs exhibited better cytotoxic profile compared to standard drug cisplatin. Detailed toxicity studies of top compound were evaluated in two cell lines, using cell viability test, apoptotic activity, oxidative stress and caspase activation and RNA-sequencing analysis, to obtain a comprehensive molecular profile of drug activity. The most effective molecule presented half maximal inhibitory concentration (IC50) values of 27 μM and 23 μM against U87 and LN229 GB cells, respectively. Same compound effectively weakened various angiogenic pathways, mainly MAPK and JAK-STAT pathways, downregulating VEGF. Transcriptome analysis identified significant promotion of apoptotic genes, and genes involved in cell cycle arrest, with concurrent inhibition of various tyrosine kinase cascades and stress response genes. Docking and immunoblotting studies suggest EGFR as a strong target of the orthothioester identified. Therefore, orthothioesters can potentially serve as a multi-dimensional chemotherapeutic possessing strong cytotoxic, anti-angiogenic and chemo-sensitization activity, challenging glioblastoma pathogenesis.
胶质母细胞瘤(GB),一种高度异质性和化疗抵抗性的四级胶质瘤,需要多维对抗剂来削弱其竞争力。考虑到之前关于硫酯类化合物作为抗肿瘤化合物的报告,本文调查了这种功能丰富的硫含量丰富的分子作为一种有效的抗GB剂的用途。对包含α-硫醚酮和正硫酯功能的12种新化合物进行生物评价,发现其中五种类似物相比标准药物顺铂表现出更好的细胞毒性特征。对最佳化合物的详细毒性研究在两种细胞系中进行了评估,使用细胞存活率测试、凋亡活性、氧化应激和caspase激活以及RNA测序分析,以获得药物活性的全面分子特征。最有效的分子在U87和LN229 GB细胞中的半数最大抑制浓度(IC50)值分别为27μM和23μM。相同的化合物有效地削弱了各种血管生成途径,主要是MAPK和JAK-STAT途径,降低了VEGF的表达。转录组分析确定了凋亡基因的显着促进,以及参与细胞周期阻滞的基因,同时抑制了各种酪氨酸激酶级联和应激反应基因。对接和免疫印迹研究表明EGFR是正硫酯酯的一个强大靶点。因此,正硫酯酯有望作为一种具有强烈细胞毒性、抗血管生成和化疗敏感性活性的多维化疗药物,挑战胶质母细胞瘤的发病机制。